Surufatinib Combined With KN046 and AG Regimen Chemotherapy as First-Line Treatment for Unresectable Advanced Pancreatic Cancer
Shanghai Zhongshan Hospital
Shanghai Zhongshan Hospital
Jiangxi Provincial Cancer Hospital
Peter MacCallum Cancer Centre, Australia
SUNHO(China)BioPharmaceutical CO., Ltd.
Al-Azhar University
Shantou University Medical College
The First Affiliated Hospital with Nanjing Medical University
Brigham and Women's Hospital
Hunan Province Tumor Hospital
BeBetter Med Inc
Qilu Pharmaceutical Co., Ltd.
Shouyao Holdings (Beijing) Co. LTD
Rise Biopharmaceuticals, Inc.
Changhai Hospital
Changhai Hospital
Zai Lab (Hong Kong), Ltd.
Rutgers, The State University of New Jersey
CureLab Oncology
Fifth Affiliated Hospital, Sun Yat-Sen University
OncoSec Medical Incorporated
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
National Cancer Institute, Naples
National Cancer Institute, Naples
National Cancer Institute, Naples
The First Affiliated Hospital with Nanjing Medical University
Tongji Hospital
Sun Yat-sen University
Sun Yat-sen University
Assiut University
Tianjin Medical University Cancer Institute and Hospital
Tianjin Medical University Cancer Institute and Hospital
Guangdong Association of Clinical Trials
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Fudan University
Sun Yat-sen University
National Cancer Centre, Singapore
Ludwig-Maximilians - University of Munich
RenJi Hospital
Sichuan University
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
The First Affiliated Hospital of Zhengzhou University
Peking Union Medical College Hospital
Samsung Medical Center
SciClone Pharmaceuticals
Fudan University
Fudan University
The Affiliated Hospital of Xuzhou Medical University
Delcath Systems Inc.
Hutchmed